NO20071354L - anvendelse av samme Butylftalid selvemulsifiserene medikamentavgivelsessystem, samt fremgangsmater for fremstilling og anvendelse av samme. - Google Patents

anvendelse av samme Butylftalid selvemulsifiserene medikamentavgivelsessystem, samt fremgangsmater for fremstilling og anvendelse av samme.

Info

Publication number
NO20071354L
NO20071354L NO20071354A NO20071354A NO20071354L NO 20071354 L NO20071354 L NO 20071354L NO 20071354 A NO20071354 A NO 20071354A NO 20071354 A NO20071354 A NO 20071354A NO 20071354 L NO20071354 L NO 20071354L
Authority
NO
Norway
Prior art keywords
same
drug delivery
delivery system
preparing
methods
Prior art date
Application number
NO20071354A
Other languages
English (en)
Other versions
NO336917B1 (no
Inventor
Zhentao Liu
Liying Yang
Hanyu Yang
Yuqing Gao
Dongmin Shen
Original Assignee
Shijiazhuang Pharma Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Pharma Group filed Critical Shijiazhuang Pharma Group
Publication of NO20071354L publication Critical patent/NO20071354L/no
Publication of NO336917B1 publication Critical patent/NO336917B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives et nytt medikamentavgivelses og frigivelsessystem, dvs. et selvemulsifiserende medikamentavgivelsessystem av butylftalid, og en fremgangsmåte for fremstilling derav og anvendelse derav i en farmasøytisk formulering. Medikamentavgivelsessystemet omfatter som essensielle ingredienser 1 % til 65 % butylftalid og 1 0 % til 65 % av et emulsifiserende middel, sammen med forskjellige eksipienter som er nødvendig avhengig av de ønskede doseringsformer. Foreliggende oppfinnelse øker signifikant kontaktarealet mellom butylftalid og den mukøse membran i den gastrointestinale trakt, og forbedrer dermed absorptive egenskaper til medikamentet.
NO20071354A 2004-08-27 2007-03-12 Butylftalid selvemulgerende medikamentavgivelsessystem, samt fremgangsmåter for fremstilling og anvendelse av samme NO336917B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2004100750682A CN100361656C (zh) 2004-08-27 2004-08-27 丁苯酞自乳化释药体系及其制备方法和应用
PCT/CN2005/001332 WO2006021160A1 (fr) 2004-08-27 2005-08-26 Système de relargage de médicament auto-émulsifiant à base de butylbenzènephtaléine, méthode de préparation et applications d’un tel système

Publications (2)

Publication Number Publication Date
NO20071354L true NO20071354L (no) 2007-05-29
NO336917B1 NO336917B1 (no) 2015-11-23

Family

ID=35926548

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071354A NO336917B1 (no) 2004-08-27 2007-03-12 Butylftalid selvemulgerende medikamentavgivelsessystem, samt fremgangsmåter for fremstilling og anvendelse av samme

Country Status (15)

Country Link
US (1) US8728518B2 (no)
EP (1) EP1787638B1 (no)
JP (1) JP4653810B2 (no)
KR (1) KR100887034B1 (no)
CN (1) CN100361656C (no)
AT (1) ATE462410T1 (no)
AU (1) AU2005276811B8 (no)
BR (1) BRPI0515070B8 (no)
CA (1) CA2578130C (no)
DE (1) DE602005020317D1 (no)
ES (1) ES2341265T4 (no)
MX (1) MX2007002335A (no)
NO (1) NO336917B1 (no)
RU (1) RU2371176C2 (no)
WO (1) WO2006021160A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100367951C (zh) 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 丁苯酞静脉乳剂及其应用
CN101342152B (zh) * 2007-07-10 2010-10-13 石药集团中奇制药技术（石家庄）有限公司 丁苯酞片及其制备方法
CN101579323B (zh) * 2008-05-16 2012-01-25 石药集团中奇制药技术（石家庄）有限公司 丁苯酞缓释片及其制备方法
CN102178643B (zh) * 2011-04-29 2014-05-14 石药集团恩必普药业有限公司 一种丁苯酞或其衍生物的微乳透皮凝胶剂及其制备方法
CN103784424B (zh) * 2012-10-30 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种丁苯酞经皮贴剂及其制备方法
CN109394720A (zh) * 2012-11-21 2019-03-01 石药集团中奇制药技术（石家庄）有限公司 一种3-正丁基苯酞衍生物的组合物及其制备方法
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN105030760B (zh) 2014-04-24 2018-10-02 长弘生物科技股份有限公司 稳定医药组合物
TWI547280B (zh) * 2014-04-24 2016-09-01 長弘生物科技股份有限公司 穩定醫藥組合物
US10799479B2 (en) 2015-04-10 2020-10-13 Bioresponse, L.L.C. Self-emulsifying formulations of DIM-related indoles
CN105267145B (zh) * 2015-11-01 2019-06-21 袁旭东 双膦酸盐的自乳化配方和相关剂型
CN105796486A (zh) * 2016-03-17 2016-07-27 南京天翔医药科技有限公司 丁苯酞脂肪乳注射剂及其制备工艺
CN107661287B (zh) * 2017-11-28 2021-01-26 遵义医学院 地榆皂苷自乳化药物传递系统的制备
CN110856712B (zh) * 2018-08-06 2021-11-30 刘超 丁苯酞自微乳组合物及其制备方法和用途
CN114073694B (zh) * 2020-08-14 2024-03-12 北京科莱博医药开发有限责任公司 丁苯酞制剂及其制备方法
CN114681389A (zh) * 2020-12-29 2022-07-01 中国科学院上海药物研究所 一种经口腔黏膜递送的丁苯酞组合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2516477B2 (ja) * 1990-12-17 1996-07-24 花王株式会社 皮膚の血行不良に起因する疾患の治療剤
CN2123000U (zh) 1992-04-24 1992-11-25 李广杰 塑料葡萄灯
DE4313693A1 (de) * 1993-04-27 1994-11-03 Bayer Ag 2-Amino-4-chinolin-dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
CN1048158C (zh) * 1993-09-09 2000-01-12 中国医学科学院药物研究所 芹菜甲素在制备预防和治疗哺乳动物或人类脑缺血引起的疾病的药中的应用
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
ATE327735T1 (de) 1998-04-01 2006-06-15 Jagotec Ag Taxan-mikroemulsionen
WO1999056727A2 (en) 1998-05-07 1999-11-11 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
CN1086942C (zh) * 1998-12-18 2002-07-03 中国医学科学院药物研究所 丁基苯酞在制备抗血栓形成及抗血小板聚集药物中的应用
MY120392A (en) * 2000-06-08 2005-10-31 Hovid Berhad A novel drug delivery system : formulation for fat-soluble drugs
US6596306B1 (en) 2000-07-07 2003-07-22 David Ho Sue San Ho Drug delivery system:formulation for fat-soluble drugs
SG97918A1 (en) 2000-06-08 2003-08-20 Hovid Sdn Bhd A novel drug delivery system: formulation for fat-soluble drugs
JP2004504342A (ja) * 2000-07-24 2004-02-12 ファルマシア・アンド・アップジョン・カンパニー 極めて水不溶性の脂肪親和性薬剤用の自己乳化性ドラッグデリバリーシステム
CN1166693C (zh) * 2001-06-18 2004-09-15 中奇制药技术（石家庄）有限公司 丁苯酞环糊精或环糊精衍生物包合物及其制备方法和用途
CN1375288A (zh) * 2002-05-13 2002-10-23 周桂荣 一种治疗脑血管疾病的药物组合物
BR0215848A (pt) * 2002-08-21 2005-06-21 Shijiazhuang Pharma Group Complexos de inclusão de butilfitalida com ciclodextrina ou seus derivados, processo para preparação destes e uso dos mesmos
JP4215633B2 (ja) 2002-12-19 2009-01-28 Ｊｆｅケミカル株式会社 複合黒鉛粒子の製造方法
CN1233317C (zh) 2003-07-07 2005-12-28 西安利君制药有限责任公司 水飞蓟素自乳化微乳组合物及其制备工艺

Also Published As

Publication number Publication date
EP1787638B1 (en) 2010-03-31
RU2371176C2 (ru) 2009-10-27
BRPI0515070B8 (pt) 2021-05-25
US8728518B2 (en) 2014-05-20
EP1787638A4 (en) 2008-12-03
BRPI0515070B1 (pt) 2020-09-08
CN1726909A (zh) 2006-02-01
AU2005276811B2 (en) 2008-11-13
RU2007111120A (ru) 2008-10-20
AU2005276811B8 (en) 2009-01-22
ES2341265T4 (es) 2011-04-27
WO2006021160A8 (en) 2006-04-13
KR20070046948A (ko) 2007-05-03
ATE462410T1 (de) 2010-04-15
KR100887034B1 (ko) 2009-03-04
AU2005276811A1 (en) 2006-03-02
CA2578130C (en) 2010-08-31
MX2007002335A (es) 2007-10-10
NO336917B1 (no) 2015-11-23
ES2341265T3 (es) 2010-06-17
US20080319056A1 (en) 2008-12-25
DE602005020317D1 (de) 2010-05-12
JP4653810B2 (ja) 2011-03-16
EP1787638A1 (en) 2007-05-23
CN100361656C (zh) 2008-01-16
CA2578130A1 (en) 2006-03-02
JP2008510737A (ja) 2008-04-10
WO2006021160A1 (fr) 2006-03-02
BRPI0515070A2 (pt) 2009-08-04

Similar Documents

Publication Publication Date Title
NO20071354L (no) anvendelse av samme Butylftalid selvemulsifiserene medikamentavgivelsessystem, samt fremgangsmater for fremstilling og anvendelse av samme.
ATE418324T1 (de) Mucoadhäsive xyloglucan-haltige formulierung für medizinprodukte und pharmazeutische darreichungsformen
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
WO2008040534A3 (en) Non-mucoadhesive film dosage forms
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
DE60121301D1 (de) Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
NO20064584L (no) Tetrahydropyridoindolderivater
WO2007149406A8 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
TW200616640A (en) Novel pharmaceutical formulations of active principles
EA201190161A1 (ru) Способ получения твердых лекарственных форм солифенацина и его фармацевтически приемлемых солей для перорального введения
ECSP045029A (es) Composiciones de valdecoxib de disgregación intraoral
MX2021010972A (es) Forma de dosificacion farmaceutica para la aplicacion a membranas mucosas y metodos para producir las mismas.
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
WO2007144080A3 (de) Antidepressiva-kombinations-wafer
WO2005058341A3 (en) Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
SE0001916D0 (sv) Novel formulation
NZ584968A (en) Novel antiretroviral combination comprising ritonavir and atazanavir
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
SE0102887D0 (sv) New formulation
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: CSPC ZHONGOI PHARMACEUTICAL TECHNOLOGY, CN